Selected research
Industry Research
Leber's Hereditary Optic Neuropathy Drug Industry Research Report 2026
Market perspective
The global Leber's Hereditary Optic Neuropathy Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Leber's Hereditary Optic Neuropathy Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Leber's Hereditary Optic Neuropathy Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Leber's Hereditary Optic Neuropathy Drug include Stealth BioTherapeutics Inc., Spark Therapeutics, Inc., Khondrion BV, Ixchel Pharma, LLC, GenSight Biologics S.A., Biovista Inc. and Alkeus Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Leber's Hereditary Optic Neuropathy Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Leber's Hereditary Optic Neuropathy Drug Market by Company
Stealth BioTherapeutics Inc.
Spark Therapeutics, Inc.
Khondrion BV
Ixchel Pharma, LLC
GenSight Biologics S.A.
Biovista Inc.
Alkeus Pharmaceuticals, Inc.
Leber's Hereditary Optic Neuropathy Drug Segment by Type
Elamipretide
KH-176
IXC-201
GS-011
Others
Leber's Hereditary Optic Neuropathy Drug Segment by Application
Hospital
Clinic
Others
Leber's Hereditary Optic Neuropathy Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leber's Hereditary Optic Neuropathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Leber's Hereditary Optic Neuropathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leber's Hereditary Optic Neuropathy Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Leber's Hereditary Optic Neuropathy Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Leber's Hereditary Optic Neuropathy Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Leber's Hereditary Optic Neuropathy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Elamipretide
- KH-176
- IXC-201
- GS-011
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Stealth BioTherapeutics Inc.
- Spark Therapeutics, Inc.
- Khondrion BV
- Ixchel Pharma, LLC
- GenSight Biologics S.A.
- Biovista Inc.
- Alkeus Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Leber's Hereditary Optic Neuropathy Drug Market Size (2021-2032)
- 2.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales (2021-2032)
- 2.2.3 Global Leber's Hereditary Optic Neuropathy Drug Market Average Price (2021-2032)
- 2.3 Leber's Hereditary Optic Neuropathy Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Elamipretide
- 2.3.3 KH-176
- 2.3.4 IXC-201
- 2.3.5 GS-011
- 2.3.6 Others
- 2.4 Leber's Hereditary Optic Neuropathy Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Leber's Hereditary Optic Neuropathy Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Leber's Hereditary Optic Neuropathy Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Leber's Hereditary Optic Neuropathy Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Leber's Hereditary Optic Neuropathy Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Leber's Hereditary Optic Neuropathy Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Leber's Hereditary Optic Neuropathy Drug, Product Type & Application
- 3.8 Global Manufacturers of Leber's Hereditary Optic Neuropathy Drug, Established Date
- 3.9 Global Leber's Hereditary Optic Neuropathy Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Stealth BioTherapeutics Inc.
- 4.1.1 Stealth BioTherapeutics Inc. Company Information
- 4.1.2 Stealth BioTherapeutics Inc. Business Overview
- 4.1.3 Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.1.5 Stealth BioTherapeutics Inc. Recent Developments
- 4.2 Spark Therapeutics, Inc.
- 4.2.1 Spark Therapeutics, Inc. Company Information
- 4.2.2 Spark Therapeutics, Inc. Business Overview
- 4.2.3 Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.2.5 Spark Therapeutics, Inc. Recent Developments
- 4.3 Khondrion BV
- 4.3.1 Khondrion BV Company Information
- 4.3.2 Khondrion BV Business Overview
- 4.3.3 Khondrion BV Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Khondrion BV Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.3.5 Khondrion BV Recent Developments
- 4.4 Ixchel Pharma, LLC
- 4.4.1 Ixchel Pharma, LLC Company Information
- 4.4.2 Ixchel Pharma, LLC Business Overview
- 4.4.3 Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.4.5 Ixchel Pharma, LLC Recent Developments
- 4.5 GenSight Biologics S.A.
- 4.5.1 GenSight Biologics S.A. Company Information
- 4.5.2 GenSight Biologics S.A. Business Overview
- 4.5.3 GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.5.5 GenSight Biologics S.A. Recent Developments
- 4.6 Biovista Inc.
- 4.6.1 Biovista Inc. Company Information
- 4.6.2 Biovista Inc. Business Overview
- 4.6.3 Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.6.5 Biovista Inc. Recent Developments
- 4.7 Alkeus Pharmaceuticals, Inc.
- 4.7.1 Alkeus Pharmaceuticals, Inc. Company Information
- 4.7.2 Alkeus Pharmaceuticals, Inc. Business Overview
- 4.7.3 Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
- 4.7.5 Alkeus Pharmaceuticals, Inc. Recent Developments
5 Global Leber's Hereditary Optic Neuropathy Drug Market Scenario by Region
- 5.1 Global Leber's Hereditary Optic Neuropathy Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021-2032
- 5.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021-2026
- 5.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2027-2032
- 5.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region: 2021-2032
- 5.3.1 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region: 2021-2026
- 5.3.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region: 2027-2032
- 5.4 North America Leber's Hereditary Optic Neuropathy Drug Market Facts & Figures by Country
- 5.4.1 North America Leber's Hereditary Optic Neuropathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
- 5.4.3 North America Leber's Hereditary Optic Neuropathy Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Leber's Hereditary Optic Neuropathy Drug Market Facts & Figures by Country
- 5.5.1 Europe Leber's Hereditary Optic Neuropathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
- 5.5.3 Europe Leber's Hereditary Optic Neuropathy Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Leber's Hereditary Optic Neuropathy Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Leber's Hereditary Optic Neuropathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Leber's Hereditary Optic Neuropathy Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Leber's Hereditary Optic Neuropathy Drug Market Facts & Figures by Country
- 5.7.1 South America Leber's Hereditary Optic Neuropathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
- 5.7.3 South America Leber's Hereditary Optic Neuropathy Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021-2032)
- 6.1.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type (2021-2032)
- 6.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Leber's Hereditary Optic Neuropathy Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021-2032)
- 7.1.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application (2021-2032)
- 7.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Leber's Hereditary Optic Neuropathy Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Leber's Hereditary Optic Neuropathy Drug Value Chain Analysis
- 8.1.1 Leber's Hereditary Optic Neuropathy Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Leber's Hereditary Optic Neuropathy Drug Production Mode & Process
- 8.2 Leber's Hereditary Optic Neuropathy Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Leber's Hereditary Optic Neuropathy Drug Distributors
- 8.2.3 Leber's Hereditary Optic Neuropathy Drug Customers
9 Global Leber's Hereditary Optic Neuropathy Drug Analyzing Market Dynamics
- 9.1 Leber's Hereditary Optic Neuropathy Drug Industry Trends
- 9.2 Leber's Hereditary Optic Neuropathy Drug Industry Drivers
- 9.3 Leber's Hereditary Optic Neuropathy Drug Industry Opportunities and Challenges
- 9.4 Leber's Hereditary Optic Neuropathy Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst